Recommendations for the diagnosis and treatment of chronic lymphocytic leukaemia (CLL) Czech Group for Chronic Lymphocytic Leukaemia, section of the Czech Society of Haematology, CzMA

Czech version

Authors: L. Smolej ¹; M. Špaček ²; P. Obrtlíková ²; Š. Pospíšilová ³; M. Jarošová ⁴; R. Urbanová ⁴; D. Lysák ⁵; M. Brejcha ⁶; J. Schwarz ⁷; M. Doubek ³
Authors‘ workplace: V. interní hematologická klinika, Fakultní nemocnice Hradec Králové a Univerzity Karlovy v Praze, Lékařská fakulta v Hradci Králové ¹; I. interní klinika – klinika hematologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecné fakultní nemocnice Praha ²; Interní hematologická a onkologická klinika, Fakultní nemocnice a Lékařské fakulty Masarykovy univerzity Brno ³; Hemato-onkologická klinika, Fakultní nemocnice a Lékařské fakulty Univerzity Palackého Olomouc ⁴; Hematologicko-onkologické oddělení, Fakultní nemocnice Plzeň ⁵; Hematologické oddělení, Nemocnice Nový Jičín ⁶; Ústav hematologie a krevní transfuze, Praha ⁷
Published in: Transfuze Hematol. dnes,22, 2016, No. 2, p. 115-126.
Category: Best Practices

Verze z 8. 3. 2016, schválená výborem ČHS ČLS JEP

Overview

Chronic lymphocytic leukaemia (CLL) has a remarkably heterogeneous clinical course. The diagnostic procedures and therapeutic interventions need to be individually tailored according to patient age, comorbidities and therapeutic aims. There have been important developments in prognostication and therapy during recent years (e. g., significance of TP53 mutations, introduction of novel monoclonal antibodies and B-cell receptor signalling inhibitors). Therefore, the Czech CLL Study Group, the working group of the Czech Society of Haematology developed these updated guidelines to facilitate the decision-making process for diagnostic and therapeutic procedures in daily practice. The guidelines are based on a comprehensive analysis of current literature and follow the principles of evidence-based medicine.

Key words:
chronic lymphocytic leukaemia – diagnosis – treatment

Sources

1. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111: 5446–5456.

2. Dearden C. B- and T-cell prolymphocytic leukemia: antibody approaches. Hematology Am Soc Hematol Educ Program 2012;2012: 645–651.

3. Moreau EJ, Matutes E, A’Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997;108: 378–382.

4. Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood 2015;126: 454–462.

5. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46: 219–234.

6. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48: 198–206.

7. Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 2015;26 Suppl 5: v78–v84.

8. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343: 1910–1916.

9. Ghia P, Stamatopoulos K, Belessi C, et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia 2007;21: 1–3.

10. Malcikova J, Pavlova S, Kozubik KS, Pospisilova S. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia. Hum Mutat 2014;35: 663–671.

11. Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol 2011;8: 38–47.

12. Pospisilova S, Gonzalez D, Malcikova J, et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012;26: 1458–1461.

13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16: 31–41.

14. Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol 2015;90: 446–460.

15. Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008;49: 49–56.

16. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998;16: 1582–1587.

17. Goede V, Cramer P, Busch R, et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica 2014;99: 1095–1100.

18. Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 1995;43: 130–137.

19. Salvi F, Miller MD, Grilli A, et al. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc 2008;56: 1926–1931.

20. Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012;30: 2820–2822.

21. Cramer P, Langerbeins P, Eichhorst B, Hallek M. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). Eur J Haematol 2016;96: 9–18.

22. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376: 1164–1174.

23. Zelenetz AD, Gordon LI, Wierda WG, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw 2015;13: 326–362.

24. Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 2015;16: 169–176.

25. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25: 5616–5623.

26. Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood 2014; 124: 19.

27. Michallet AS, Rossignol J, Cazin B, Ysebaert L. Rituximab-cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leuk Lymphoma 2011;52: 1401–1403.

28. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370: 1101–1110.

29. Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia 2015;29: 1602–1604.

30. Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 2015;385: 1873–1883.

31. Michallet AS, Aktan M, Schuh A, et al. MABLE: Rituximab in combination with bendamustine or chlorambucil for the treatment of chronic lymphocytic leukemia: primary results from the randomized phase IIIb MABLE study. XVI. International Workshop on CLL 2015, abstract 88.

32. Hillmen P, Gribben JG, Follows GA, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. J Clin Oncol 2014;32: 1236–1241.

33. Offner F, Panagiotidis P, Afanasyev B, et al. Ofatumumab and bendamustine combination therapy in patients with untreated and relapsed chronic lymphocytic leukemia: initial results of the phase II study OMB115991. XV. International Workshop on CLL 2013, abstract 4.2.

34. Smolej L, Brychtova Y, Doubek M, et al. Low-dose FCR is a safe and effective treatment option for elderly/comorbid patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Updated results of project Q-Lite by Czech CLL Study Group. Blood 2014;124: 4670.

35. Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371: 213–223.

36. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370: 997–1007.

37. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99: 3554–3561.

38. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27: 3994–4001.

39. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29: 3559–3566.

40. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28: 1756–1765.

41. Badoux XC, Keating MJ, Wang X, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011;117: 3016–3024.

42. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28: 1749–1755.

43. Smolej L, Doubek M, Panovska A, et al. Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia. Leuk Res 2012;36: 1278–1282.

44. Doubek M, Brychtova Y, Panovska A, et al. Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia. results from a phase II study. Am J Hematol 2015;90: 417–421.

45. Durot E, Michallet AS, Lepretre S, Le QH, Leblond V, Delmer A. Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter’s syndrome: results of a French retrospective multicenter study. Eur J Haematol 2015;95: 160–167.

46. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369: 32–42.

47. Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015;125: 2497–2506.

48. Bottcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012;30: 980–988.

49. Logan AC, Zhang B, Narasimhan B, et al. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia 2013;27: 1659–1665.

50. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007;21: 12–17.

51. Dreger P, Schetelig J, Andersen N, et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood 2014;124: 3841–3849.

52. Rossi D, Gaidano G. Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol 2009;27: 1–10.

53. Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. Blood 2014;123: 1647–1657.

54. Parikh SA, Shanafelt TD. Risk factors for Richter syndrome in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2014;9: 294–299.

55. Osterborg A, Foa R, Bezares RF, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009;23: 1980–1988.

56. Smolej L. Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice? Blood 2008;112: 2167.

57. Smolej L, Procházka V, Špaček M, et al. Doporučení pro léčbu alemtuzumabem u chronické lymfocytární leukémie (CLL). Vnitř Lék 2012;58(3): 232–236.

58. Oscier D, Dearden C, Eren E, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol 2012;159: 541–564.

59. Dhalla F, Lucas M, Schuh A, et al. Antibody deficiency secondary to chronic lymphocytic leukemia: Should patients be treated with prophylactic replacement immunoglobulin? J Clin Immunol 2014;34: 277–282.

60. Shanafelt T. Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers. Hematology Am Soc Hematol Educ Program 2013;2013: 158–167.

61. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43: 258–270.

62. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47: 8–32.

63. Tsimberidou AM, Wen S, McLaughlin P, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 2009;27: 904–910.

64. Idelalisib (Zydelig) – Souhrn údajů o přípravku (SPC). Dostupné na www: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_- _Product_Information/ human/003843/WC500175377.pdf. Stránka navštívena 3.5.2016.

Labels

Haematology Internal medicine Clinical oncology

Analysis of the relationship of cytogenetic results with serum free light chain ratio κ/λ(FLC-r, FreeliteTM), heavy/light chain pairs of immunoglobulin ratio (HLC-r, HevyliteTM), and selected prognostic factors assessed at diagnosis of multiple myeloma

Application of interphase fluorescence in situ hybridisation for the analysis of CD34+ cells in peripheral blood of patients with myelodysplastic syndromes

Prophylaxis versus on demand treatment in adult patients with severe haemophilia A – FN Brno experience

Single center experience with the treatment of older patients with myelodysplastic syndrome, not eligible for intensive therapy and its financial consequences

Indications for allogeneic and autologous haematopoietic cell transplantations in the Czech Republic in 2016: Recommendations of the Transplant Section of the Czech Society of Haematology and the Czech Society of Oncology of the J. E. Purkyně Medical Association

Article was published in

Transfusion and Haematology Today

2016 Issue 2